Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?
CTC (circulation tumor cells)
biomarkers
ctDNA (circulating tumor DNA)
liver cancer
transplant
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
05
2022
accepted:
04
07
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Liver transplant (LT) is the most favorable treatment option for patients with early stage hepatocellular carcinoma (HCC). Numerous attempts have been pursued to establish eligibility criteria and select HCC patients for LT, leading to various systems that essentially integrate clinico-morphological variables. Lacking of sufficient granularity to recapitulate the biological complexity of the disease, all these alternatives display substantial limitations and are thus undeniably imperfect. Liquid biopsy, defined as the molecular analysis of circulating analytes released by a cancer into the bloodstream, was revealed as an incomparable tool in the management of cancers, including HCC. It appears as an ideal candidate to refine selection criteria of LT in HCC. The present comprehensive review analyzed the available literature on this topic. Data in the field, however, remain scarce with only 17 studies. Although rare, these studies provided important and encouraging findings highlighting notable prognostic values and supporting the contribution of liquid biopsy in this specific clinical scenario. These results underpinned the critical and urgent need to intensify and accelerate research on liquid biopsy, in order to determine whether and how liquid biopsy may be integrated in the decision-making of LT in HCC.
Identifiants
pubmed: 36033451
doi: 10.3389/fonc.2022.940473
pmc: PMC9402935
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
940473Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Gonvers, Tabrizian, Melloul, Dormond, Schwartz, Demartines and Labgaa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Investig Med. 2018 Jun;66(5):1-6
pubmed: 29632031
Lancet Oncol. 2015 Jul;16(7):804-15
pubmed: 26088272
Hepatology. 2004 Mar;39(3):792-7
pubmed: 14999698
JAMA Surg. 2022 Jun 1;157(6):524-530
pubmed: 35353121
J Hepatol. 2016 Aug;65(2):305-13
pubmed: 27132171
J Hepatol. 2017 Aug;67(2):282-292
pubmed: 28267620
Ann Transl Med. 2020 Sep;8(17):1067
pubmed: 33145286
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Hepatology. 2022 Feb;75(2):455-472
pubmed: 34859465
Am J Transplant. 2019 Dec;19(12):3250-3262
pubmed: 31162867
Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534
pubmed: 28210698
Transplant Proc. 2016 Nov;48(9):2962-2965
pubmed: 27932119
Br J Cancer. 2015 Feb 3;112(3):532-8
pubmed: 25584485
Liver Transpl. 2018 Jul;24(7):946-960
pubmed: 29624843
Oncol Lett. 2018 Apr;15(4):5481-5488
pubmed: 29552189
Transplantation. 2008 Jan 15;85(1):81-7
pubmed: 18192916
Liver Int. 2021 Mar;41(3):562-573
pubmed: 33205544
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1444-52
pubmed: 25791790
Sci Rep. 2018 Aug 1;8(1):11570
pubmed: 30068984
Gastroenterology. 2021 Nov;161(5):1502-1512
pubmed: 34331914
Surgery. 2002 Jan;131(1):34-43
pubmed: 11812961
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Transplant Proc. 2015 Nov;47(9):2639-42
pubmed: 26680058
J Cell Biochem. 2018 Jun;119(6):4711-4716
pubmed: 29278659
Discov Med. 2015 Apr;19(105):263-73
pubmed: 25977189
Liver Int. 2020 Dec;40(12):3103-3116
pubmed: 32614460
Hepatol Commun. 2021 Mar 23;5(6):1095-1105
pubmed: 34141992
JAMA Oncol. 2017 Apr 01;3(4):493-500
pubmed: 27838698
Adv Exp Med Biol. 2016;924:25-28
pubmed: 27753013
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Clin Cancer Res. 2018 Feb 1;24(3):547-559
pubmed: 29070526
J Cancer. 2021 Oct 22;12(23):7190-7200
pubmed: 34729120
Ann Surg. 2011 Oct;254(4):569-76
pubmed: 21892074
Transplant Proc. 2006 Dec;38(10):3636-9
pubmed: 17175353
Lancet Oncol. 2020 Jul;21(7):947-956
pubmed: 32615109
Liver Transpl. 2022 Apr;28(4):593-602
pubmed: 34626159
Asian J Surg. 2022 Jan;45(1):435-440
pubmed: 34426060
Liver Transpl. 2008 Aug;14(8):1107-15
pubmed: 18668667
Ann Surg. 2016 May;263(5):842-50
pubmed: 26779979
Gut Liver. 2022 May 15;16(3):443-455
pubmed: 34737243
Liver Transpl. 2020 Jun;26(6):823-831
pubmed: 32061009
Liver Transpl. 2022 Feb;28(2):200-214
pubmed: 34664394
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Int J Cancer. 2019 Mar 15;144(6):1444-1452
pubmed: 30338850
Surg Oncol. 2020 Jun;33:276-281
pubmed: 32561093
Oncogene. 2018 Jul;37(27):3740-3752
pubmed: 29628508
J Clin Med. 2020 May 20;9(5):
pubmed: 32443763
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Transpl Int. 2007 Jul;20(7):576-82
pubmed: 17425725
Cancers (Basel). 2021 Feb 06;13(4):
pubmed: 33562173
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Hepatol Commun. 2020 Aug 04;4(10):1527-1540
pubmed: 33024921
PLoS One. 2020 Sep 22;15(9):e0239386
pubmed: 32960907
Oncotarget. 2016 Apr 12;7(15):19824-39
pubmed: 26918346
Int J Mol Sci. 2022 May 10;23(10):
pubmed: 35628154
Liver Transpl. 2002 Sep;8(9):765-74
pubmed: 12200775
Transpl Int. 2021 Dec;34(12):2875-2886
pubmed: 34784081
PLoS One. 2021 Mar 12;16(3):e0247917
pubmed: 33711036
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Hepatology. 2015 Jul;62(1):158-65
pubmed: 25777590
Clin Chim Acta. 2004 Sep;347(1-2):129-38
pubmed: 15313150
Hepat Mon. 2011 Mar;11(3):195-9
pubmed: 22087143
Cancers (Basel). 2021 May 19;13(10):
pubmed: 34069569
Oncogene. 2021 Jan;40(1):140-151
pubmed: 33097857
Gut. 2021 Jul 28;:
pubmed: 34321221
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394